USP’s Sheehan and Liu talk at AAPS PharmSci 360 abou getting novel excipients past the monograph hurdle through early engagement with FDA.
|Articles|May 2, 2017
Baxter BioPharma Solutions
Advertisement
Whether you face formulation challenges, clinical supply hurdles, surges in demand due to market fluctuations, risk mitigation concerns, or patent expiry challenges, we offer tailored, versatile solutions-and more than 80 years of parenteral experience-to help you achieve your commercialization objectives. Our goal is to make you feel confident in choosing BioPharma Solutions as your CMO-assisting with the unexpected through marketplace complexities.
One Baxter Parkway, Deerfield, IL 60015
biopharmasolutions@baxter.com
tel.1.800.422.9837
International: 1.224.948.4770
CPhI North America Booth #2454
Advertisement
Related to this article
CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
The business case for regulated AI turns on the cost of producing an outcome that the quality system can accept.
In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.
Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
Structural modifications can improve peptide stability, solubility, and absorption to enable effective oral delivery.
The FDA approves VOCERYQ, the first DNA medicine, for RRP surgery reduction, raising plasmid, drug-device, and confirmatory trial manufacturing demands.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Improving Oral Peptide Delivery Through Structural Modifications
3
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
4
Who Answers for Your Data? Building a Life Sciences Data Mesh
5